Navigation Links
Solos Endoscopy, Inc. is Primed for Growth in 2012
Date:12/29/2011

BOSTON, Dec. 29, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company looks towards continued growth in 2012 through the development and sales of its high quality instruments for the screening, diagnosis, treatment and management of medical conditions. In 2011, Solos Endoscopy consummated agreements, which resulted in the forgiveness of approximately $300,000 in debt for the Company. The signed settlement agreement and new consulting agreement resulted in a reduction of ongoing expenses by approximately $40,000 per quarter that will carry over into 2012.

Throughout the year, Solos has focused its R & D efforts into the design and development of new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). These advantages include reduced pain due to smaller incisions and hemorrhaging, and shorter recovery time.

With a focus on relentless improvement, the Company announced the launch of its Veterinary Product Line of endoscopic equipment, scopes and instruments in June of 2011.The Solos Veterinary Product Line consists of more than 48 SKUs with prices ranging from $75 to $3900. According to the American Pet Product Association, in 2009, Consumers spent more than $45 Billion on their pets, with more than $12 Billion spent on Vet Care.

In conjunction with the introduction of the Veterinary Product Line, Solos launched its newly designed and interactive website, www.solosendoscopy.com on July 1, 2011. The updated look showcases streamlined navigation to allow for easy-to-use functionality, allowing users to quickly reference desired information making it easier for Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States to identify and select from Solos' vast product line, which includes the Company's successful MammoView® instrument line.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

The Solos MammoView® system is currently in use at various teaching hospitals across the United States.  Patients should be aware that mammary ductoscopy, utilizing the MammoView® system, is a means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging that can reveal evidence of the disease. From July through November, mammary ductoscopy instrument sales accounted for approximately 40% of the total sales for the period.

"We are pleased with our efforts in 2011. We remain committed to our shareholders, vendors and those we supply and are appreciative of their support in 2012," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:
Amanda Segersten,
rsegersten@solosendoscopy.com


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
2. Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
3. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
4. Solos Endoscopy Goes Google
5. Solos Endoscopy Finishes the 3rd Quarter Strong
6. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
7. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
8. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
9. Solos Endoscopy to Reduce Debt by Over $620,000
10. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
11. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017  CANTEL MEDICAL CORP. (NYSE: ... President and CEO, will be presenting at the 16 th ... Grand Central Hotel in New York . ... at 3:00 p.m. ET. In addition, management will be available ... A live audio webcast will be available via the investor ...
(Date:3/22/2017)... 2017  Ablation is the minimally invasive therapeutic ... of purposes, from cancerous or diseased tissue removal, ... in atrial fibrillation and others. The growing adoption ... to innovate and improvise existing ablation technologies for ... global market is expected to grow at high ...
(Date:3/22/2017)... LINCOLN, Mass. , March 22, 2017 /PRNewswire/ ... applying mechanistic modeling to drug research and development, ... QSP Day 2017.  QSP Day 2017 is a ... with the quantitative systems pharmacology (QSP) community. The ... mathematical modeling is de-risking and accelerating drug research ...
Breaking Medicine Technology:
(Date:3/22/2017)... NJ (PRWEB) , ... March 22, 2017 , ... ... Group, the nation’s leading digital and print media enterprise focused on cancer patients, ... video content, has released a special 12-part educational video series, “No Ifs, Ands, ...
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the ... HIV, reports Leslie Norins, MD, PhD. He says investigating this possibility, is ... Zika virus and in new infections with HIV. , His findings appear ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Last year, ... to a US Department of Agriculture report. While excess dairy can be caused ... a role. Lactose sensitivity is the inability to properly digest lactose, a sugar found ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long Island ... County region, is embarking on a combined charity effort with the Great Neck Breast ... last 25 years, the Great Neck Breast Cancer Coalition has worked to support breast ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to families and business owners in the greater Nassau County area, ... & Lymphoma Society. , Every 3 minutes, someone in America is diagnosed with ...
Breaking Medicine News(10 mins):